SC
RLMD icon

Steven Cohen’s Relmada Therapeutics RLMD Stock Holding History

Steven Cohen’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-70,000
Closed -$2.59M – 1750
2022
Q3 		$2.59M Buy
+70,000
New +$1.94M 0.01% 870

Other funds holding RLMD

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JHC
Jones Hill Capital New York $470M AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Steven Cohen's RLMD Position: Q2 2026 in Review

Steven Cohen sold out of Relmada Therapeutics (RLMD) in Q2 2026, closing a stake of 504,820 shares — an estimated $3.51M sold.

Steven Cohen first reported a position in RLMD in Q4 2019 and held it in 15 quarters. The position peaked at $35.4M in Q1 2022. 126 funds tracked by Wall St. Rank hold RLMD as of Q2 2026.

  • Steven Cohen reported no remaining Relmada Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Steven Cohen sold 504,820 Relmada Therapeutics shares in Q2 2026, an estimated $3.51M.
  • Steven Cohen first reported a position in Relmada Therapeutics in Q4 2019 and held it in 15 quarters.
  • Steven Cohen's Relmada Therapeutics position peaked at $35.4M in Q1 2022.
  • 126 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q2 2026.

Based on Point72 Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.